Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.39 |
| ▸ | CKS1B | P61024 | 2/20 | 0.37 |
| ▸ | SKP1 | P63208 | 2/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.37 |
| ▸ | TTK | P33981 | 8/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | RPTOR | Q8N122 | 2/20 | 0.35 |
| ▸ | MLST8 | Q9BVC4 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874327 | 0.93 | DGAT1 (0.41) | DGAT1CKS1BSKP1SKP2TTK | |
| SCHEMBL10277566 | 0.90 | DGAT1 (0.39) | DGAT1MTORRPTORMLST8JAK1 | |
| SCHEMBL6889988 | 0.90 | DGAT1 (0.39) | DGAT1MTORRPTORMLST8JAK1 | |
| SCHEMBL10237617 | 0.88 | DGAT1 (0.38) | DGAT1CKS1BSKP1SKP2TTK | |
| SCHEMBL31025 | 0.88 | HPGDS (0.40) | DGAT1MTORRPTORMLST8 | |
| SCHEMBL2705740 | 0.87 | DGAT1 (0.41) | DGAT1MTORRPTORMLST8JAK1 | |
| SCHEMBL10237593 | 0.86 | DGAT1 (0.40) | DGAT1CKS1BSKP1SKP2TTK | |
| SCHEMBL7878601 | 0.86 | DGAT1 (0.40) | DGAT1CKS1BSKP1SKP2TTK | |
| SCHEMBL2679956 | 0.86 | DGAT1 (0.42) | DGAT1MTORRPTORMLST8JAK1 | |
| SCHEMBL17399398 | 0.86 | MTOR (0.45) | DGAT1MTORRPTORMLST8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MERCK SHARP & DOHME LLC | 2012-05-10 | — | — | US | disclosed |
| WO-2010118207-A1 | PYRAZOLO [1, 5-A] PYRIMIDINE DERIVATIVES AS MTOR INHIBITORS | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120114739-A1 | PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS | MTOR, RICTOR, RPTOR | DGAT1 3031/4885CKS1B 504/4885SKP1 1474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.